General Ophthalmology

17-32 of 381

• 

  RestartResume

  Clinical and Safety Outcomes from the LIGHTSITE III Trial

  RestartResume

  Clinical and Safety Outcomes from the LIGHTSITE III Trial

  MinuteCE®

  Clinical and Safety Outcomes from the LIGHTSITE III Trial

  David Boyer, MD; Diana V. Do, MD

  1.00 program credit

  • 

    

    David Boyer, MD

  • 

    

    Diana V. Do, MD

  1.00 program credit

• 

  RestartResume

  Sustaining Visual Benefits of Photobiomodulation in Dry Age-Related Macular Degeneration

  RestartResume

  Sustaining Visual Benefits of Photobiomodulation in Dry Age-Related Macular Degeneration

  MinuteCE®

  Sustaining Visual Benefits of Photobiomodulation in Dry Age-Related Macular Degeneration

  Marion Munk, MD, Ph.D; David Boyer, MD

  1.00 program credit

  • 

    

    Marion Munk, MD, Ph.D

  • 

    

    David Boyer, MD

  1.00 program credit

• 

  RestartResume

  Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications

  RestartResume

  Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications

  MinuteCE®

  Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications

  Marion Munk, MD, Ph.D; David Boyer, MD

  1.00 program credit

  • 

    

    Marion Munk, MD, Ph.D

  • 

    

    David Boyer, MD

  1.00 program credit

• 

  RestartResume

  Patient-Centered Care and Integration of Photobiomodulation Therapy into Clinical Practice

  RestartResume

  Patient-Centered Care and Integration of Photobiomodulation Therapy into Clinical Practice

  MinuteCE®

  Patient-Centered Care and Integration of Photobiomodulation Therapy into Clinical Practice

  Diana V. Do, MD; Marion Munk, MD, Ph.D

  1.00 program credit

  • 

    

    Diana V. Do, MD

  • 

    

    Marion Munk, MD, Ph.D

  1.00 program credit

• 

  RestartResume

  Integration of Photobiomodulation Therapy into the Age-Related Macular Degeneration Treatment Landscape

  RestartResume

  Integration of Photobiomodulation Therapy into the Age-Related Macular Degeneration Treatment Landscape

  MinuteCE®

  Integration of Photobiomodulation Therapy into the Age-Related Macular Degeneration Treatment Landscape

  David Boyer, MD; Marion Munk, MD, Ph.D

  1.00 program credit

  • 

    

    David Boyer, MD

  • 

    

    Marion Munk, MD, Ph.D

  1.00 program credit

• 

  RestartResume

  Anatomical Outcomes from the LIGHTSITE III Trial

  RestartResume

  Anatomical Outcomes from the LIGHTSITE III Trial

  MinuteCE®

  Anatomical Outcomes from the LIGHTSITE III Trial

  Diana V. Do, MD; David Boyer, MD

  1.00 program credit

  • 

    

    Diana V. Do, MD

  • 

    

    David Boyer, MD

  1.00 program credit

• 

  RestartResume

  Shared Care Perspectives: Retina and Optometry

  RestartResume

  Shared Care Perspectives: Retina and Optometry

  CME/CE

  Shared Care Perspectives: Retina and Optometry

  John Kitchens, MD; Sara LeMay, OD

  0.25 credits

  • 

    

    John Kitchens, MD

  • 

    

    Sara LeMay, OD

  0.25 credits

• 

  RestartResume

  Diagnosing and Tracking the Progression of MacTel Type 2

  RestartResume

  Diagnosing and Tracking the Progression of MacTel Type 2

  MinuteCE®

  Diagnosing and Tracking the Progression of MacTel Type 2

  Thomas Albini, MD; Roger A. Goldberg, MD, MBA

  1.00 program credit

  • 

    

    Thomas Albini, MD

  • 

    

    Roger A. Goldberg, MD, MBA

  1.00 program credit

• 

  RestartResume

  An Overview of Current Management Limitations

  RestartResume

  An Overview of Current Management Limitations

  MinuteCE®

  An Overview of Current Management Limitations

  Thomas Albini, MD; Roger A. Goldberg, MD, MBA

  1.00 program credit

  • 

    

    Thomas Albini, MD

  • 

    

    Roger A. Goldberg, MD, MBA

  1.00 program credit

• 

  RestartResume

  Quality of Life in MacTel Type 2 

  RestartResume

  Quality of Life in MacTel Type 2 

  MinuteCE®

  Quality of Life in MacTel Type 2 

  Dean Eliott, MD; Charles C. Wykoff, MD, PhD, FACS

  1.00 program credit

  • 

    

    Dean Eliott, MD

  • 

    

    Charles C. Wykoff, MD, PhD, FACS

  1.00 program credit

• 

  RestartResume

  Beyond BCVA: Measuring Functional Vision in MacTel Type 2

  RestartResume

  Beyond BCVA: Measuring Functional Vision in MacTel Type 2

  MinuteCE®

  Beyond BCVA: Measuring Functional Vision in MacTel Type 2

  Thomas Albini, MD; Roger A. Goldberg, MD, MBA

  1.00 program credit

  • 

    

    Thomas Albini, MD

  • 

    

    Roger A. Goldberg, MD, MBA

  1.00 program credit

• 

  RestartResume

  New Therapies: The Basics

  RestartResume

  New Therapies: The Basics

  MinuteCE®

  New Therapies: The Basics

  Thomas Albini, MD; Roger A. Goldberg, MD, MBA

  1.00 program credit

  • 

    

    Thomas Albini, MD

  • 

    

    Roger A. Goldberg, MD, MBA

  1.00 program credit

• 

  MinuteCE®

  Rethinking MacTel: Cell-based Insights for Vision Preservation

  Thomas Albini, MD; Roger A. Goldberg, MD, MBA

  1.00 credit 10 episodes

  • 

    

    Thomas Albini, MD

  • 

    

    Roger A. Goldberg, MD, MBA

  • 

    

    Dean Eliott, MD

  • 

    

    Charles C. Wykoff, MD, PhD, FACS

  1.00 credit 10 episodes

• 

  RestartResume

  MacTel Type 2: A Misnomer?

  RestartResume

  MacTel Type 2: A Misnomer?

  MinuteCE®

  MacTel Type 2: A Misnomer?

  Dean Eliott, MD; Charles C. Wykoff, MD, PhD, FACS

  1.00 program credit

  • 

    

    Dean Eliott, MD

  • 

    

    Charles C. Wykoff, MD, PhD, FACS

  1.00 program credit

• 

  RestartResume

  Analyzing Clinical Trial Data: Part 1

  RestartResume

  Analyzing Clinical Trial Data: Part 1

  MinuteCE®

  Analyzing Clinical Trial Data: Part 1

  Thomas Albini, MD; Roger A. Goldberg, MD, MBA

  1.00 program credit

  • 

    

    Thomas Albini, MD

  • 

    

    Roger A. Goldberg, MD, MBA

  1.00 program credit

• 

  RestartResume

  The Road Ahead – Integrating Research Into Practice

  RestartResume

  The Road Ahead – Integrating Research Into Practice

  MinuteCE®

  The Road Ahead – Integrating Research Into Practice

  Dean Eliott, MD; Charles C. Wykoff, MD, PhD, FACS

  1.00 program credit

  • 

    

    Dean Eliott, MD

  • 

    

    Charles C. Wykoff, MD, PhD, FACS

  1.00 program credit